-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UYdvJZ3K0Hd+TbyduBHAwitl8gZ3taUM1fvYwDgqwbagfXv7710noNRDj/5HbIVz vsYhJn+e/EW2NSWM19B2gg== 0000920148-00-500019.txt : 20001214 0000920148-00-500019.hdr.sgml : 20001214 ACCESSION NUMBER: 0000920148-00-500019 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20001212 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20001212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LABORATORY CORP OF AMERICA HOLDINGS CENTRAL INDEX KEY: 0000920148 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 133757370 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-11353 FILM NUMBER: 787962 BUSINESS ADDRESS: STREET 1: 358 S MAIN ST STREET 2: 4225 EXECUTIVE SQ STE 800 CITY: BURLINGTON STATE: NC ZIP: 27215 BUSINESS PHONE: 3362291127 MAIL ADDRESS: STREET 1: 358 S MAIN ST STREET 2: 4225 EXECUTIVE SQ SUITE 800 CITY: BURLINGTON STATE: NC ZIP: 27215 FORMER COMPANY: FORMER CONFORMED NAME: NATIONAL HEALTH LABORATORIES HOLDINGS INC DATE OF NAME CHANGE: 19940314 8-K 1 form8k.txt FORM 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DECEMBER 12, 2000 - ------------------ (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS - ------------------------------------------ (Exact name of registrant as specified in its charter) DELAWARE 1-11353 13-3757370 -------------- ----------- -------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification incorporation) Number) 358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215 - ------------------------------------------------------- (Address of principal executive offices) 336-229-1127 - ------------ (Registrant's telephone number, including area code) ITEM 5. OTHER EVENTS Laboratory Corporation of America -Registered Trademark- Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced the introduction HIV GENOSURE-Trademark-, a new genotypic resistance assay, to its portfolio of HIV resistance testing services. This latest offering from LabCorp, called HIV GENOSURE -Trademark-, is designed to yield a more sensitive assay at low viral load levels, improve the turnaround time for results, and provide a more user friendly, single page report. These attributes of HIV GENOSURE -Trademark- will aid physicians in providing better and faster patient care. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS (c) Exhibit 20 Press release of the Company dated December 12, 2000. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LABORATORY CORPORATION OF AMERICA HOLDINGS ------------------------------------------ (Registrant) By:/s/ BRADFORD T. SMITH ---------------------------------- Bradford T. Smith Executive Vice President, General Counsel, Secretary and Compliance Officer Date: December 12, 2000 EX-20 2 genosure12-4pr.txt COMPANY PRESS RELEASE Laboratory Corporation of America -Registered Trademark- Holdings 358 South Main Street Burlington, NC 27215 Telephone: 336-584-5171 FOR IMMEDIATE RELEASE Contact: 336-436-4855 Shareholder Direct: 800-LAB-0401 Pamela Sherry www.labcorp.com LABCORP-REGISTERED TRADEMARK- INTRODUCES HIV GENOSURE- TRADE MARK- A NEW HIV GENOTYPIC RESISTANCE ASSAY Burlington, NC, December 12, 2000 - Laboratory Corporation of America-REGISTERED TRADEMARK- Holdings (LabCorp- REGISTERED TRADEMARK-) (NYSE: LH) today announced the introduction HIV GENOSURE-TRADE MARK- , a new HIV genotypic resistance assay, to its portfolio of HIV resistance testing services. This latest offering from LabCorp, called HIV GENOSURE- TRADE MARK- is designed to yield a more sensitive assay at low viral load levels, improve the turnaround time for results, and provide a more user friendly, single page report. These attributes of HIV GENOSURE-TRADE MARK- will aid physicians in providing better and faster patient care. Developed using the company's database of over 40,000 genotypic and phenotypic specimens, HIV GENOSURE-TRADE MARK- allowed LabCorp to create a proprietary mutational cluster analysis (MCA) software program to interpret genotypic results providing an easily readable "sensitive", "resistance possible" and "resistant" interpretation for each antiviral drug. HIV GENOSURE-TRADE MARK- was developed as a LabCorp in-house initiative to improve the current resistance testing available to HIV patients. As compared to other HIV genotypic resistance tests currently available, HIV GENOSURE-TRADE MARK- has improved: the sensitivity at low viral load levels, the turn around time for results, and the completeness of the patient report by providing delineation of mutations identified per antiviral drug. LabCorp was one of the first laboratories to offer innovative HIV resistance testing to physicians in the United States, and is a leader in terms of experience and expertise in this field. Additionally, LabCorp now provides more options for ordering genotype analysis: an HIV genotyping test with MCA interpretation (HIV GENOSURE- TRADE MARK-) or a genotyping test plus a predictive phenotype result using a correlation database (HIV GENOSURE-TRADE MARK- Plus). Besides these genotype offerings, LabCorp will continue to provide phenotype testing through its existing corporate partnerships. This will allow physicians to choose the most appropriate resistance test for their patients when they utilize LabCorp as their reference lab. "As one of the largest providers of HIV testing services in the United States, we are committed to advancing the state of the art in genotypic resistance testing," said Myla P. Lai-Goldman, M.D., executive vice president, chief scientific officer and medical director at LabCorp. "The introduction of HIV GENOSURE-TRADE MARK- will give physicians and patients improved resistance testing options." Laboratory Corporation of America-REGISTERED TRADEMARK- Holdings (LabCorp-REGISTERED TRADE MARK-) is a national clinical laboratory with annual revenues of $1.7 billion in 1999. With 18,000 employees and over 100,000 clients nationwide, the company offers more than 2,000 clinical tests ranging from simple blood analyses to sophisticated molecular diagnostics. LabCorp leverages its expertise in innovative clinical testing technology with its Centers of Excellence. The Center for Molecular Biology and Pathology, in Research Triangle Park (RTP), North Carolina, develops applications for polymerase chain reaction (PCR) technology, and National Genetics Institute in Los Angeles is an industry leader in developing novel, highly sensitive PCR methods for testing hepatitis C and other infectious agents. Its Center for Occupational Testing in RTP is one of the world's largest substance abuse testing facilities, and the Center for Esoteric Testing in Burlington, North Carolina, performs the largest volume of specialty testing in the network. LabCorp's clients include physicians, state and federal government, managed care organizations, hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other clinical laboratories. Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 1999 and subsequent SEC filings. ### 3 - - more - -----END PRIVACY-ENHANCED MESSAGE-----